QPPV.COM KNOWLEDGE ASSESSMENT

Avacopan: Drug-Induced Liver Injury and Vanishing Bile Duct Syndrome

Test your understanding of the concepts covered by Avacopan: Drug-Induced Liver Injury and Vanishing Bile Duct Syndrome.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A patient has cholestatic liver-test abnormalities and pruritus after starting avacopan, but no biopsy has been performed. What is the most appropriate case description?
Question 2 of 10 A safety team is comparing FDA’s March 2026 communication with the current US prescribing information. What is the best way to manage differences in monitoring schedules or thresholds?
Question 3 of 10 Which interpretation of the ADVOCATE treatment comparison is consistent with the article?
Question 4 of 10 Which statement best characterises the UK position as of 3 October 2026?
Question 5 of 10 Which interpretation correctly handles the reported fatalities in FDA’s DILI and VBDS case series?
Question 6 of 10 A pharmacovigilance scientist is asked to estimate the incidence of avacopan-associated DILI from the 76 reported cases. What is the most appropriate response?
Question 7 of 10 Which information set would most strengthen assessment of a suspected avacopan-related liver injury?
Question 8 of 10 Which conclusion is justified by the fact that six of the seven reported VBDS cases came from Japan and one from Canada?
Question 9 of 10 Why should a rechallenge generally not be undertaken simply to clarify causality when serious DILI or VBDS is suspected?
Question 10 of 10 As of 3 October 2026, what was the status of FDA’s proposed withdrawal of US approval?

Select an answer to continue.

QPPV.com